Search results
Tom Burke defends speech and content across all mediums – representing internet companies; networks; studios; book, magazine and news publishers; and authors, journalists, photographers, documentary filmmakers, and environmental groups.
Thomas R. Burke is a Continuing Lecturer of Media Law at the Graduate School of Journalism where he has taught since 2002. He is a partner at Davis Wright Tremaine LLP in San Francisco and Co-Chair of the firm’s national media law practice.
Thomas R. Burke is known for Call Jane (2022), The Endless (2017) and Synchronic (2019).
Nov 3, 2022 · NOV. 3, 2022 – Over a three-decade career, Thomas R. Burke has advanced the cause of free speech for clients ranging from investigative journalists to nonprofit global advocacy groups to the world's most popular digital platforms. He has secured victories that have consistently broken bar.
Tom Burke defends speech and content across all mediums – representing internet companies; networks; studios; book, magazine and news publishers; and authors, journalists, photographers, documentary filmmakers, and environmental groups.
Thomas R. Burke is a partner and co-chair of Davis Wright Tremaine LLP's Media Practice. Mr. Burke practices in DWT's San Francisco office and is the author of Anti-SLAPP Litigation (The Rutter Group, 2016).
Thomas R. Burke, an attorney with Davis Wright Tremaine LLP in San Francisco, California, helps clients address Media and Advertising situations. He received legal training from University of San Francisco School of Law. He graduated from law school in 1989.
Oct 20, 2022 · Burke is the author of "Anti-SLAPP Litigation" (The Rutter Group 2013-present) and a contributing editor to "Weil & Brown, Cal. Practice Guide: Civil Procedure Before Trial" (The Rutter Group 2014-present) (Anti-SLAPP Motions).
Davis Wright Tremaine LLP - Cited by 11 - First Amendment - Anti-SLAPP Litigation
Thomas Burke Aim: To determine real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer (NSCLC) with programmed death ligand-1...
